Company / R&D per Share
AGIOS PHARMACEUTICALS, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$5.94
FY2025
5-year range
$4.06 / $5.94
FY2021-FY2025
Trend
+10.3%
vs FY2024
Sector context
#24 of 208
Health Care
What the data says
AGIOS PHARMACEUTICALS, INC.'s r&d per share of $5.94 is higher than 88% of companies in the Health Care sector (FY2025). R&D per Share has increased for 3 consecutive years, from $4.06 in FY2022 to $5.94 in FY2025.
Based on SEC 10-K filings.
5.94 in FY2025 with a 5-year CAGR of +3.5%. Top quartile in the Health Care sector.
Improved from $5.37 to $5.94 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.5%
- 5-Year CAGR
- +3.5%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 208This company $5.94 Sector average $12.19
▼
-51.3% below sector average
Key checks
Key Insights
- AGIOS PHARMACEUTICALS, INC.'s r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 10.3% year-over-year.
- Ranks #24 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.94 | +10.3% |
| FY2024 | $5.39 | +0.3% |
| FY2023 | $5.37 | +32.1% |
| FY2022 | $4.06 | -4.4% |
| FY2021 | $4.25 | -14.8% |
| FY2020 | $4.99 | +35.6% |
| FY2019 | $3.68 | -18.4% |
| FY2018 | $4.51 | -35.0% |
| FY2017 | $6.93 | +18.7% |
| FY2016 | $5.84 | +297.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026